Diagnosis and Management of Urothelial Carcinoma of the Bladder

References

• . National Comprehensive Cancer Network (NCCN) 2011 Guidelines for Bladder Cancer. http://www.nccn.org. Accessed March 25, 2011
   Google Scholar
• . Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics 2010. CA Cancer J Clin. 2010;60(5);277–300
   PubMed Web of Science ®Google Scholar
• . Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer. 2009;115(1):68–74
   PubMed Web of Science ®Google Scholar
• . Hecht SS. Cigarette smoking: cancer risks, carcinogens, and mechanisms. Langenbecks Arch Surg. 2006;391(6):603–613
   PubMedGoogle Scholar
• . Brennan P, Bogillot O, Cordier S,. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer. 2000;86(2):289–294
   PubMed Web of Science ®Google Scholar
• . International Agency for Research on Cancer. Tobacco smoke involuntary smoking. IARC monographs on the evaluation of carcinogenic risks to humans. Vol 83. Lyon, France: IARC; 2004:53–119
   Google Scholar
• . Vineis P, Pirastu R. Aromatic amines and cancer. Cancer Causes Control. 1997;8(3):346–355
   PubMed Web of Science ®Google Scholar
• . Nilsson S, Ullén A. Chemotherapy-induced bladder cancer. Scand J Urol Nephrol Suppl. 2008;218:89–92
   Google Scholar
• . Levine LA, Ritchie JP. Urological complications of cyclophosphamide. J Urol. 1989;141(5):1063–1069
   PubMedGoogle Scholar
• . Talar-Williams C, Hijazi YM, Walther MM,. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1997;124(5):477–484
   Google Scholar
• . Takamoto S, Sakura N, Namere A, Yashiki M. Monitoring of urinary acrolein concentration in patients receiving cyclophosphamide and ifosphamide. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;806(1):59–63
   PubMedGoogle Scholar
• . Nortier JL, Martinez MC, Schmeiser HH,. UC associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342:1686–1692
   PubMed Web of Science ®Google Scholar
• . Kleinerman RA, Boice JD Jr, Storm HH,. Secondary primary cancer after treatment for cervical cancer. An international regestries study. Cancer. 1995;76(3):442–452
   PubMedGoogle Scholar
• . Bostrom PJ, Soloway MS, Manoharan M, Ayyathurai R, Samavedi S. Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy. J Urol. 2008;179(1):91–95
   PubMed Web of Science ®Google Scholar
• . Travis LB, Curtis RE, Storm H,. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997;89(19):1429–1439
   PubMedGoogle Scholar
• . Kogevinas M, 't Mannetje A, Cordier S,. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control. 2003;14(10):907–914
   PubMed Web of Science ®Google Scholar
• . Gago-Dominguez M, Castelao JE, Yuan JM, Yu MC, Ross RK. Use of permanent hair dyes and bladder-cancer risk. Int J Cancer. 2001;91(4):575–579
   PubMedGoogle Scholar
• . Michaud DS, Spiegelman D, Clinton SK,. Fluid intake and the risk of bladder cancer in men. N Engl J Med. 1999;340(18):1390–1397
   PubMedGoogle Scholar
• . Lin J, Spitz MR, Dinney CP,. Bladder cancer risk as modified by family history and smoking. Cancer. 2006;107(4):705–711
   PubMedGoogle Scholar
• . Kaderlik KR, Kadlubar FF. Metabolic polymorphisms and carcinogen-DNA adduct formation in human populations. Pharmacogenetics. 1995;5:S108–S117
   Google Scholar
• . Vineis P, Marinelli D, Autrup H,. Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiol Biomarkers Prev. 2001;10(12):1249–1252
   PubMedGoogle Scholar
• . Wilson CM, McPhaul MJ. A and B forms of the androgen receptor are expressed in a variety of human tissues. Mol Cell Endocrinol. 1996;120(1):51–57
   PubMedGoogle Scholar
• . Boorjian SA, Heemers HV, Frank I,. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer. 2009;16(1):123–137
   PubMedGoogle Scholar
• . Krege JH, Hodgin JB, Couse JF,. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proac Natl Acad Sci USA. 1998;95(26):15677–15682
   PubMed Web of Science ®Google Scholar
• . Madeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol. 2004;22(2):86–92
   PubMedGoogle Scholar
• . Groah SL, Weitzenkamp DA, Lammertse DP,. Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil. 2002;83(3):346–351
   PubMedGoogle Scholar
• . Michaud DS, Platz EA, Giovannucci E. Gonorrhea and male bladder cancer in a prospective study. Br J Cancer. 2007;96(1):169–171
   PubMedGoogle Scholar
• . Soergel TM, Cain MP, Misseri R, Gardner TA, Koch MO, Rink RC. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol. 2004;172(4 pt 2):1649–1651
   PubMedGoogle Scholar
• . Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5(9):713–725
   PubMed Web of Science ®Google Scholar
• . Cheng L, Zhang S, MacLennan GT, Williamson Sr, Lopez-Beltran A, Montironi R. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol. 2001;42(4):455–481
   Google Scholar
• . Chou R, Dana T. Screening adults for bladder cancer. A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2010;153(7):461–468
   PubMed Web of Science ®Google Scholar
• . Wasco MJ, Daignault S, Zhang Y,. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology. 2007;70(1):69–74
   PubMed Web of Science ®Google Scholar
• . Black PC, Brown GA, Dinney CP. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol. 2009;27(1):3–7
   PubMedGoogle Scholar
• . Zhai QJ, Black J, Ayala AG, Ro JY. Histologic variants of infiltrating urothelial carcinoma. Arch Pathol Lab Med. 2007;131(8):1244–1256
   PubMedGoogle Scholar
• . Wang X, MacLennan GT, Lopez-Beltran A, Cheng L. Small cell carcinoma of the urinary bladder–histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis. Appl Immunohistochem Mol Morphol. 2007;15(1):8–18
   PubMedGoogle Scholar
• . Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol. 2005;13(2):143–153
   PubMed Web of Science ®Google Scholar
• . MacLennan GT, Kirkali Z, Cheng L. Histologic grading of non-invasive papillary urothelial neoplasms. Eur Urol. 2007;51(4);889–898
   PubMed Web of Science ®Google Scholar
• . Williamson SR, Montironi R, Lope-Beltran A, MacLennan GT, Davidson DD, Cheng L. Diagnosis, evaluation and treatment of carcinoma insitu of the urinary bladder: the state of the art. Crit Rev Oncol Hematol. 2010;76(2):112–126
   PubMedGoogle Scholar
• . Grossfeld GD, Wolf JS Jr, Litwan MS,. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am Fam Physician. 2001;63(6):1145–1154
   PubMedGoogle Scholar
• . Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000;163(2):524–527
   PubMed Web of Science ®Google Scholar
• . Grossfeld GD, Litwin MS, Wolf JS,. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy–part I: definition, detection, prevalence, and etiology. Urology. 2001;57(4):599–603
   PubMed Web of Science ®Google Scholar
• . Denzinger S, Burger M, Walter B,. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology. 2007;69(4):675–679
   PubMed Web of Science ®Google Scholar
• . Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? Urology. 2002;60(6):1025–1028
   PubMed Web of Science ®Google Scholar
• . Fradet Y, Grossman HB, Gomella L,. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007;178(1):68–73
   PubMed Web of Science ®Google Scholar
• . Schumacher MC, Holmang S, Davidsson T, Friedrich B, Pedersen J, Wiklund NP. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomized, multicentre study. Eur Urol. 2010;57(2):293–299
   PubMed Web of Science ®Google Scholar
• . Brausi M, Collette L, Kurth K,; EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523–531
   PubMed Web of Science ®Google Scholar
• . Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999;162(1):74–76
   PubMed Web of Science ®Google Scholar
• . Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003;61(1):109–118
   PubMed Web of Science ®Google Scholar
• . Schroeder GL, Lorenzo-Gomez MF, Hautmann SH,. A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol. 2004;172(3):1123–1126
   PubMed Web of Science ®Google Scholar
• . Lokeshwar VB, Schroeder GL, Selzer MG,. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer. 2002;95(1):61–72
   PubMedGoogle Scholar
• . Bassi P, De Marco V, De Lisa A,. Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol Int. 2005;75(3):193–200
   PubMedGoogle Scholar
• . Grossman HB, Messing E, Soloway M,. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293(7):810–816
   PubMed Web of Science ®Google Scholar
• . Attallah AM, Sakr HA, Ismail H, Abdel-Hady el-SK, El-Dosoky I. An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer. BJU Int. 2005;96(3):334–339
   PubMedGoogle Scholar
• . Konety BR, Nguyen TS, Dhir R,. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res. 2000;6(7):2618–2625
   PubMed Web of Science ®Google Scholar
• . Myers-Irvin JM, Landsittel D, Getzenberg RH. Use of the novel markers BLCA-1 for the detection of bladder cancer. J Urol. 2005;174(1):64–68
   PubMedGoogle Scholar
• . Lokeshwar VB, Selzer MG. Urinary bladder tumor markers. Urol Oncol. 2006;24(6):528–537
   PubMedGoogle Scholar
• . Lokeshwar VB, Obek C, Pham HT,. Urinary hyaluronic acid and hyluronidase: markers for bladder cancer detection and evaluation of grade. J Urol. 2000;163(1):348–356
   PubMed Web of Science ®Google Scholar
• . Okegawa T, Kinjo M, Horie S, Nutahara K, Higashihara E. Detection of mucin 7 gene expression in exfoliated cells in urine from patients with bladder tumor. Urology. 2003;62(1):182–186
   PubMedGoogle Scholar
• . Black PC, Brown GA, Dinney CP. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol. 2006;24(35):5528–5535
   PubMedGoogle Scholar
• . Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol. 2008;26(6):646–651
   PubMed Web of Science ®Google Scholar
• . Chrysochou C, Power A, Shurrab AE,. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol. 2010;5(3):484–489
   PubMed Web of Science ®Google Scholar
• . Edge SB, Byrd DR, Compton CC, eds. Urinary bladder. In: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:367–374
   Google Scholar
• . Dutta SC, Smith JA Jr, Shappell SP, Coffey CS, Chang SS, Cookson MS. Clinical understaging of high-risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001;166(2):490–493
   PubMed Web of Science ®Google Scholar
• . Stein JP, Lieskovski G, Cote R,. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–675
   PubMed Web of Science ®Google Scholar
• . Grossman HB, Natale RB, Tangen CM,. Neoadjuvant chemotherapy plus cystectomy compared to cystectomy alone locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–866
   PubMed Web of Science ®Google Scholar
• . Quek ML, Stein JP, Nichols PW,. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol. 2005;174(1):103–106
   PubMedGoogle Scholar
• . Palmieri F, Brunocilla E, Bertaccini A,. Prognostic value of lymphovascular invasion in bladder cancer in patients treated with radical cystectomy. Anticancer Res. 2010:30(7):2073–2076
   PubMedGoogle Scholar
• . Shabsigh A, Bochner BH. Use of normograms as predictive tools in bladder cancer. World J Urol. 2006;24(5):489–498
   PubMedGoogle Scholar
• . Bochner BH, Kattan MW, Vora KC. Postoperative normogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol. 2006:24:3967–3972
   PubMed Web of Science ®Google Scholar
• . Karakiewicz PI, Shariat SF, Palapattu GS,. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 2006:176:1354–1361
   PubMed Web of Science ®Google Scholar
• . Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006;24(5):778–789
   PubMed Web of Science ®Google Scholar
• . Mitra AP, Pagliarulo V, Yang D, Waldman FM, Datar RH, Skinner DG. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol. 2009;27(24):3929–3937
   PubMedGoogle Scholar
• . Karam JA, Lotan Y, Karakiewicz PI,. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007;8(2):128–136
   PubMedGoogle Scholar
• . Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22(6):1014–1024
   PubMed Web of Science ®Google Scholar
• . Bajorin DF, Dodd PM, Mazumdar M. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–3181
   PubMed Web of Science ®Google Scholar
• . Lutzeyer W, Rübben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol. 1982;127(2):250–252
   PubMedGoogle Scholar
• . Heney NM, Ahmed S, Flanagan MJ,. Superficial bladder cancer: progression and recurrence. J Urol. 1983;130(6):1083–1086
   PubMed Web of Science ®Google Scholar
• . Sylvester RJ, van der Meijden AP, Oosterlinck W,. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466
   PubMed Web of Science ®Google Scholar
• . Hall MC, Chang SS, Dalbagni G,. Guidelines for the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis): 2007 update. J Urol. 2007;178(6):2314–2330
   PubMed Web of Science ®Google Scholar
• . Babjuk M, Oosterlinck W, Sylvester R,. EAU guidelines on non-muscle urothelial carcinoma of the bladder. Eur Urol. 2008;54(2):303–314
   PubMed Web of Science ®Google Scholar
• . Prescott S, Jackson AM, Hawkyard SJ, Alexandroff AB, James K. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms. Clin Infect Dis. 2000;31( suppl 3):S91–S93
   Google Scholar
• . Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol. 2003;170(3):964–969
   PubMed Web of Science ®Google Scholar
• . Shelley MD, Court JB, Kynaston H,. Intravesical Bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2000;4:CD001986
   Google Scholar
• . Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964–1970
   PubMed Web of Science ®Google Scholar
• . Lamm DL, Blumenstein BA, Crissman JD,. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–1129
   PubMed Web of Science ®Google Scholar
• . Brake M, Loertzer H, Horsch R, Keller H. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer. Urology. 2000;55(5):673–678
   PubMed Web of Science ®Google Scholar
• . Lamm DL. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am. 1992;19(3):565–572
   PubMedGoogle Scholar
• . Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmetteguerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174(1):86–91
   PubMed Web of Science ®Google Scholar
• . Steinberg G, Bahnson R, Brosman S,. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000;163(3):761–767
   PubMed Web of Science ®Google Scholar
• . Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr,. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990;143(3):502–506
   PubMed Web of Science ®Google Scholar
• . Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004;63(4):682–687
   PubMed Web of Science ®Google Scholar
• . Shariat SF, Karakiewicz PI, Palapattu GS,. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006;176(6 pt 1):2414–2422
   PubMedGoogle Scholar
• . Madersbacher S, Hochreiter W, Burkhard F,. Radical cystectomy for bladder cancer today–a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003;21:690–696
   PubMed Web of Science ®Google Scholar
• . Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomized controlled trial. International Collaboration of Trialists. Lancet. 1999;354(9178):533–540
   PubMedGoogle Scholar
• . Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):202–206
   PubMed Web of Science ®Google Scholar
• . Von der Maase H, Hansen SW, Roberts JT,. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–3077
   PubMed Web of Science ®Google Scholar
• . Advancerd Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005;48(2):189–201
   PubMedGoogle Scholar
• . Shipley WU, Kaufman DS, Heney NM, Althausen AF, Zietman AL. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. J Urol. 1999;162(2):445–451
   PubMedGoogle Scholar
• . Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol. 1998;16(4):1298–1301
   PubMed Web of Science ®Google Scholar
• . James N, Hussain S, Hall E,: Results of a 2 × 2 phase III randomized trial of synchronous chemo-radiotherapy compared to radiotherapy alone and standard versus reduced high volume RT in muscle invasive bladder cancer. Abstract 4. Presented at: 52nd American Society for Radiation Oncology Annual Meeting; October 31, 2010 to November 4, 2010; San Diego, CA
   Google Scholar
• . Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997;15(12):3441–3445
   PubMed Web of Science ®Google Scholar
• . Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997;15(11):3394–3398
   PubMed Web of Science ®Google Scholar
• . Kaufman D, Raghavan D, Carducci M,. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18(9):1921–1927
   PubMed Web of Science ®Google Scholar
• . Von der Masse H, Andersen L, Crino L, Weinknecht S, Dogliotti L. Weekly gemcitabine and cisplatin therapy in patients with transicional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol. 1999;10(12):1461–1465
   PubMedGoogle Scholar
• . Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic trasitional-cell carcinoma of the urothelium. Lancet Oncol. 2010;11(9):861–870
   PubMedGoogle Scholar
• . Dogliotti L, Carteni G, Siena S,. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007;52(1):134–141
   PubMed Web of Science ®Google Scholar
• . Bellmunt J, Theodore C, Demkov T,. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–4461
   PubMed Web of Science ®Google Scholar
• . Bellmunt J, Paz-Ares L, Cuello M,. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007;18(3):522–528
   PubMed Web of Science ®Google Scholar